Motivation: Detailed knowledge of coding sequences has led to different candidate models for pathogenic variant prioritization. Several deleteriousness scores have been proposed for the noncoding part of the genome, but no large-scale comparison has been realized to date to assess their performance.
Introduction
The non-coding genome was long considered to be junk DNA (Ohno, 1972) due to its largely unknown function. The decrease of the cost of whole genome sequencing (WGS) over the last decade has favored the screening of this large part of the genome (>98%) and the progress in non-coding genome analysis has allowed defining different functional regions. Most of them are regulatory elements driving gene expression (Khurana et al., 2016) , such as gene promoters, enhancers, or binding sites for proteins or RNA. In the past 5 years, several tools have been developed to identify noncoding pathogenic variants. The deleterious impact of mutations in these regions, which comes mostly from alterations in gene expression (Khurana et al., 2016; Poliseno et al., 2015; Yarmishyn and Kurochkin, 2015) , is more difficult to measure and interpret than qualitative traits, such as non-sense/missense mutations in the coding sequence, owing to their complex, varying, or simply unknown modes of action. Due to the large number of benign non-coding mutations, the computational identification of pathogenic variants is more challenging in the non-coding genome than in the coding genome.
One category of methods for discriminating pathogenic variants from benign variants in the non-coding part of the genome aims to identify functional regions, which are more likely to possess pathogenic mutations than non-functional regions. They are based on two concepts: germline selection and somatic selection. The concept of germline selection has been used for a long time to identify functional coding regions. Unlike the non-functional part of the genome, important functional regions should be conserved over successive generations, presenting polymorphism with low frequency, due to purifying (negative) selection of deleterious variants. Selection tends to stabilize important functional regions, so that polymorphisms are rare compared to non-functional regions. The computational methods in this category, viz., CADD (Kircher et al., 2014) , DANN (Quang et al., 2015) , Funseq2 (Fu et al., 2014) and the SNP (Li et al., 2015a) , do not directly model the pathogenicity status of a variant, but rather the polymorphism rate of particular regions. The main difference between these methods is the type of polymorphism considered: the proportion of rare polymorphisms among all polymorphisms [SNP (Li et al., 2015a) ], the polymorphism rate in the 1000 genomes project (The 1000 Genomes Project Consortium, 2015) [Funseq2 (Fu et al., 2014) ], or the deviation of allele frequency in the 1000 genomes project (The 1000 Genomes Project Consortium, 2015) [CADD (Kircher et al., 2014) and DANN (Quang et al., 2015) ] from the neutral model.
There is increasing evidence that genetic variation in many complex quantitative traits results from the joint small effects of multiple variants (Ward and Kellis, 2012; Weng et al., 2011) . A simulation study realized by Caballero et al. (Caballero et al., 2015) suggested that variants with moderate effects on a complex trait, such as cancer, may be present with moderate frequencies in the population due to a weaker selection than that of the variants with higher impacts. This weak selection at the population level prevents the identification of these functional regions using the germline selection concept. Another way to circumvent this issue would be to look for conservation at the intra-individual level. It is now accepted that we can define cancer specific somatic mutation landscapes (Alexandrov et al., 2013) resulting from selection pressures which differ from those of the germline selection. Genomic sequences with a reduced tumor somatic mutation rate in terms of somatic mutations may reflect their functional importance for a tumor's development, especially when their mutation lead to a loss or gain of function (Khurana et al., 2016) . Li et al. (Li et al., 2015a) recently used this concept to complete the germline conservation concept for the identification of non-coding pathogenic variants. Their different SOM (SOMatic) scores are predictors of somatic mutation density for different cancer types based on Encode and other annotated genome features. A low SOM score indicates a region with low expected mutation density which is more likely to harbor driver mutation.
The last type of common methods to identify pathogenic variants is based on machine learning techniques that implement a prediction model with different features (including some conservation scores) to predict the pathogenicity status of a variant. In this category, FATHMM-MKL (Shihab et al., 2015) and GWAVA (Ritchie et al., 2014) are the most commonly used methods to score non-coding variants.
A recent comparison of these tools showed that their variant prioritization is not consistent. The overlap of the 10 000 highest deleterious TCGA liver non-coding somatic mutations according to CADD, FATHMM-MKL, Funseq2, GWAVA and RegulomeDB contained only 13 variants ( 1&) (Li et al., 2015b) . The divergence of these results suggests that the question of the prioritization of deleterious variants is far from being solved. Identifying the strengths and limitations of these methods is a difficult task since they are based on different concepts, different algorithms and use their own sets of features. We propose here to compare the predictive performance of the previously mentioned approaches using different pathogenic benchmark databases representing particular genomic contexts. We evaluated the sensitivity, specificity and precision of each method using a benign variant database [variants from 1000 genomes project (1KG) (The 1000 Genomes Project Consortium, 2015)] and two pathogenic databases [ClinVar (Landrum et al., 2014) and COSMIC (Forbes et al., 2008) variants].
Materials and methods

Benchmark databases
We first removed, from all the databases, all variants at positions referred to as coding DNA sequences (CDS), start or stop codon in the GENCODE annotation database (Harrow et al., 2006) , in order to focus on the non-coding part of the genome.
Two pathogenic databases were considered: the ClinVar variants (downloaded 4 January 2016) labeled as pathogenic (CLNSIG code 5) and the COSMIC (CosmicNCV file, v80, Grch37) non-coding variants identified in whole-genome sequencing which is currently the most exhaustive somatic mutations database as it includes, amongst other, somatic mutations of ICGC and TCGA projects. Since the pathogenic status of COSMIC variants was not certain, we assumed that the likelihood of their pathogenic status increased with their recurrence in tumor samples. We tested several recurrence thresholds (from 1 to 20) for performing the sensitivity analysis. We removed HGMD variant positions (Stenson et al., 2009) (Version 2014/04/14, 166 768 variants) from all these databases to avoid overfitting of GWAVA and FATHMM-MKL, which used the HGMD database during their training step.
We considered two control databases: the ClinVar variants labeled as benign (CLNSIG code 2) and the 1KG phase 3 polymorphisms for its wide genome coverage and its relatively homogeneous WGS protocol (The 1000 Genomes Project Consortium, 2015).
We removed the variants of the two pathogenic databases, HGMD variants and 1KG variants with AF < 1% from the databases to reduce the risk of the inclusion of pathogenic variants. We drew two control sets from the remaining variants. Firstly, we defined an unmatched control set including all benign variants (for the ClinVar database) or including 100 000 polymorphisms randomly sampled (for the 1KG database). This sample size for 1KG is a compromise between representativeness and computation time. We checked this representativeness realizing a sensitivity analysis using 10 different randomly sampled unmatched 1KG control sets which did not show substantial changes in the results (< 1%). Secondly, we defined a regional control set including the variants in the 1 kb surrounding each variant of the pathogenic database considered. This regional control set reduced the sampling bias of pathogenic variants, testing the discrimination in a more homogeneous context.
Annotation and scoring
We annotated the variants using all alternative transcripts from the comprehensive GENCODE annotation database release 19 (current UCSC version for GRCh37), without transcript consideration, to obtain a summary of the characteristics of the variant locations.
The scoring of the databases was realized using the pre-computed databases of the different methods (CADD v1.3; DANN v1.0; Funseq2 v2.1; SNP and SOM scores v1.0) . We compared the four disease specific SOM scores proposed by Li et al. (Li et al., 2015a) , which we denote by SOM CLL (chronic lymphocytic leukemia), SOM liver , SOM lung and SOM melanoma .
Since the available pre-computed GWAVA database did not cover the whole genome, we used the software application GWAVA v1.0 to score the variants with the three scores proposed by this tool trained using different control sets (Ritchie et al., 2014) , which we will refer to as GWAVA unmatched (random 1KG variants), GWAVA TSS [all 1KG SNPs in the 2 kb windows surrounding an annotated TSS (transcription start site) and including HGMD variants] and GWAVA region (1KG variants in the 1 kb surrounding each of the HGMD training set variants).
Overall, 12 different scoring methods (including the 3 GWAVA scores and the 4 SOM scores) were evaluated in the current comparison. A short description of these methods is provided in the Supplementary Table S1 .
The source code of our pipeline is freely available from https:// github.com/ Oncostat/BenchmarkNCVTools and can be used to further add prediction methods.
Evaluation criteria
The true positive rate (TPR, i.e. the sensitivity or the recall) and the false positive rate (FPR, i.e. one minus the specificity) of the different methods were compared using their area under the receiver operating characteristic (ROC) curves (AUC ROC ). Formal definitions of these indicators are provided in the Supplementary Material. A random classifier will have an ROC curve close to the diagonal with AUC ROC equal to 0.5.
In order to break potential ties, the precision-recall (PR) curve (Davis and Goadrich, 2006) provided another point of comparison through the precision criterion, i.e. the proportion of true pathogenic variants predicted as such (the positive predictive value, PPV), which is equal to one minus the false discovery rate (FDR). In de novo pathogenic mutation searches, this criterion has to be maximized in order to avoid driving the pathogenic validation studies in the wrong direction. The precision of the different methods was compared using their area under the precision-recall (PR) curves (AUC PR ). A random classifier will have a PR curve close to the horizontal line at a precision value equal to the prevalence of the pathogenic variants in the sample. 95% confidence intervals of AUC were computed using 2000 bootstrap iterations.
We added the term decreasing to denote the scores for which the most accurate pathogenic predictions was obtained by the lower scores (decreasing scale).
These analyses were realized using the package PRROC (v1.1) of the R software (v3.3.3-2017-03-06).
Results
GENCODE features of the pathogenic databases
A complete description of the distribution of the features of the pathogenic databases is provided in Supplementary Table S2 and Figure S1 . The Supplementary Table S2 shows the proportions of variants with at least one transcript harboring the feature. In order to compare these databases with the training set that was used for the development of FATHMM-MKL and GWAVA, the transcript feature frequencies of the HGMD database are also indicated.
The feature distributions of the ClinVar and HGMD databases were quite similar. The variants were mostly located in proteincoding transcripts (> 95%), processed transcripts (> 24%), retained introns (> 24%) and non-sense mediated decay transcripts (> 20%).
COSMIC variants differed from ClinVar variants through their lower frequency of protein coding transcript positions and their higher frequency of pseudogene transcript positions. These trends were even more visible when the recurrence threshold was increased. The proportion of variants associated to protein coding transcripts decreased with the number of occurrences (from 48.70% to 18.48%) whereas the proportion of variants associated to pseudogene transcripts increased quickly with the number of occurrences (from 5.24% to 51.09%). A large proportion of COSMIC variants were located in regions without known transcripts (between 22.78% and 39.72%), compared to 0.75% of the ClinVar variants.
ClinVar benchmark
Three groups may be distinguished using their ROC and PR curves ( Fig. 1 and Supplementary Fig. S4 ). The first group includes CADD, DANN and FATHMM-MKL, which had the best sensitivity and specificity (AUC ROC 0.95) and precision (AUC PR 0.82). The second group includes Funseq2, GWAVA and the SNP score, which had also good sensitivity and specificity (0.72 AUC ROC 0.82), but a lower precision than the first group (0.20 AUC PR 0.37). The third group includes only the SOM scores, which provided the worst performance according to these criteria (AUC ROC 0.52, AUC PR 0.14). The difference between these three groups was more pronounced in the regional benchmark ( Supplementary Fig.  S11 ).
The sub-optimal results of the SOM scores may be explained in large part by the genome segmentation used by this score, which is not defined according to features, but on 1 Mb windows. The loss of heterogeneity induced by these windows, considered as homogeneous, decreases the information with which to discriminate pathogenic variants from their neighborhoods. This is especially true for the regional benchmark, in which the SOM score cannot distinguish the pathogenic variants from their 1 kb window neighborhoods (AUC ROC 0.50). We note that our assumed pathogenic variants were associated with lower SOM scores (indicated by the decreasing term) as expected by its authors.
FATHMM-MKL and GWAVA trained their machine learning algorithms on the HGMD database, which has a feature distribution close to that of the ClinVar database. The better performance of FATHMM-MKL may due to its larger number of features (763 using the 4-feature groups, i.e. 46-way sequence conservation, histone modifications, transcription factor binding sites and open chromatine). Although the sensitivity, specificity and precision of GWAVA substantially decreased in the more homogeneous context of the regional benchmark, FATHMM-MKL maintained a high discrimination power thanks to a combination of features defining a high resolution genome segmentation. Unlike the germline conservation-based tools, there may, however, be some overoptimism in the performance evaluation of FATHMM-MKL and GWAVA, due to their training on the HGMD database. This may explain why, in both performance groups, tools based on learning over known pathogenic variants had an AUC ROC with slightly higher false discovery rate than those based on germline conservation (CADD, DANN and SNP) for the unmatched benchmark.
For this benchmark, CADD, DANN and FATHMM-MKL had the best sensitivity and specificity, but CADD and DANN clearly outperformed the other germline conservation-based tools (Funseq2 and SNP score) in terms of precision. This may be related to the higher number of features in the model, but also to the higher consistency of its germline conservation model compared to the 1KG allele frequency used by other tools.
These trends were confirmed and accentuated using 1KG SNPs control set ( Supplementary Figs. S5 and S12). The better performance of all tools was explained by the greater difference of feature distribution between 1KG and ClinVar pathogenic variants.
COSMIC benchmark
Using the ClinVar benign variants control set, the results were the inverse of what was expected: the higher scores (lower for SOM scores) were attributed to 1KG polymorphisms (Fig. 2,  Supplementary Table S3 ). Only the trends of SOM Liver and GWAVA scores were in accordance with expectations, but they were close to a random classifier (AUC ROC 0.50). These trends were similar using the ClinVar benign variants in the regions of COSMIC variants. We only present the results of the threshold of 2 and 3 recurrences in the Supplementary Material because there was no regional control for the higher thresholds.
Using the 1KG control set, all scores had low sensitivity and specificity in discriminating variants observed at least three times in the COSMIC database from the 1KG polymorphisms (AUC ROC 0.60). Their performance increased significantly when we considered the variants observed at least four times (AUC ROC 0.78, Supplementary Table S5, Fig. 3) , and kept increasing slightly up to AUC ROC ¼ 0.90 (GWAVA unmatched for a recurrence threshold of 10). The precision of all scores was close to the prevalence, whatever the recall (sensitivity), resulting in values of AUC PR close to the prevalence (Supplementary Table S6 , Supplementary Fig. S3 ), suggesting that all scores had a large FPR.
Germline-based tools (CADD, DANN, Funseq2, SNP) were outperformed by the others in this benchmark. The performance of DANN was close to a random classifier (AUC ROC 0.50). Pathogenic variants were associated with the lower SNP scores, which was opposite of the expectation. Surprisingly, SOM liver , which had a sub-optimal performance in the ClinVar benchmark, was, depending on the recurrence threshold used, second or third for this benchmark. The performance of SOM CLL seemed similar to that of the germline concept based tools, but those from SOM lung and SOM melanoma scores were close to a random classifier. We can note that the ranking of the SOM scores is related to the COSMIC variants' primary site origin prevalence (55% liver, 13% haematopoietic and lymphoid tissue, 1% skin, > 1% lung), but also to the characteristics of the training set of these scores. The performance of the SOM liver score, higher than the SOM CLL score despite a higher somatic mutation number, might potentially be attributed to its larger sample size (n liver ¼ 88, n CLL ¼ 28). In the regional benchmark, FATHMM-MKL was the top performer, possibly due to its high resolution in genome segmentation, as mentioned above (Supplementary Tables S9 and S10 , and Supplementary Fig. S10 ). In contrast, the low resolution in genome segmentation of the SOM scores may explain their precisions' being close to that of a random classifier, in accordance with their AUC ROC . But, unlike the ClinVar benchmark, regional evaluation did not reduce the performance of all scores. The better result of Funseq2 with the regional versus unmatched benchmark may be explained by overfitting due to its training on an older version (v68) Fig. 3. ROC curves of the different tools for the discrimination of COSMIC variants (observed at least four times) from 100 000 unmatched 1KG polymorphisms recurrent COSMIC variants. As less than 5% of the COSMIC variants are located in the 2 kb window around TSS, the better result of GWAVA TSS in this benchmark than in the unmatched benchmark could not be explained by a potential overfitting due to its training set's being specific to TSS regions. More investigations are required to explain this improved performance.
Discussion
To the best of our knowledge, the present paper is the first to assess the behavior of the current non-coding variant prioritization scores in different genomic contexts. We used two reference databases, ClinVar and COSMIC, which differ significantly in terms of feature distribution, defining different genomic contexts. The discrimination of ClinVar pathogenic variants was acceptable for all the scores, especially for CADD, DANN and FATHMM-MKL, but it was more problematic for the recurrent COSMIC variants. Based on the common rated scores, our ranking based on the ClinVar benchmark is similar to that of the recent large scale comparison of Liu et al. (Liu et al., 2017 ) except for FATHMM-MKL which performed the best in their study (FATHMM-MKL >CADD >DANN >Funseq2). However, this difference may be influenced by some overfitting of FATHMM-MKL due to their use of HGMD variants as the sole positive dataset. In addition, our benchmark showed that this ranking depends on the genomic context, such as for our COSMIC benchmark where GWAVA and SOM scores may be better alternatives.
The theoretical comparison of all these methods is complex due to the variety of models and training sets. Gagliano et al. (Gagliano et al., 2015) showed that the choice of the annotation dataset may have higher influence than the choice of the algorithm. Our results complete their statement, suggesting that an algorithm using a high genome resolution segmentation has a real advantage in terms of precision, as illustrated by FATHMM-MKL and the counterexample of the SOM scores. Based on 1 Mb windows, the SOM scores assign the same score to all nucleotides in the same window, making it impossible to discriminate pathogenic variants.
However, this advantage could also lead to overfitting the training set and provide highly biased predictions if the training set are a biased sample. Therefore, in the context of the whole genome screening, obtaining consistent pathogenic status of thousands variants such as for the ClinVar and HGMD projects has a substantial drawback for the model training. The validation of the variant status requires a substantial human, technical, and financial investment, placing a focus on variants which are the most likely to be deleterious according to current knowledge. For example, Nishizaki et al. (Nishizaki and Boyle, 2017) investigated the effect on transcription of SNP predicted to be deleterious by four methods, including CADD and FATHMM-MKL. Conservation-based methods have been around for a while and led to several regions that may include pathogenic variants, mainly in the protein coding regions. In this process, variants in the non-coding regions, mistakenly considered as junk, are left aside, restraining the genome coverage of pathogenic variant databases to the coding regions. This sampling bias was already mentioned by the authors of GWAVA in reference to the HGMD database (Ritchie et al., 2014) , which has a feature distribution very close to that of ClinVar (98.92% and 95.69% of variants in protein coding gene regions, respectively). Using new knowledge brought by the validation of variant status in these regions, the models trained on current pathogenic databases are refinement of conservation-based models. This is especially so because the training sets of FATHMM-MKL and GWAVA (HGMD) included only germline variants (Stenson et al., 2014) . It could therefore have been expected that all the tools but SOM-which was trained on somatic mutations-should perform well on the ClinVar pathogenic dataset, which includes 79% germline variants. While this ensures more precise prediction in these regions, one should not expect the same prediction performance in the rest of the genome. The fact that all tools considered the COSMIC mutations less pathogenic than the ClinVar benign variants supports this hypothesis.
As far as the results of the COSMIC benchmark were concerned, the scores based on this concept were not among the best performers for discriminating COSMIC variants, which mostly include noncoding variants possibly involved in expression regulation. The complex and quantitative attributes of expression suggest that selection may be weaker for these positions than for coding region positions (Caballero et al., 2015) . As mentioned above, the resulting population heterogeneity may explain why germline conservation-based tools are not appropriate for discriminating the COSMIC variants.
In this context, the good results of the SOM scores, relatively to the others, highlights the value of the somatic conservation concept. Interestingly, the ranking of these scores seems related to the sample size of their training sets and, more importantly, to the primary tumour site of each variant in the COSMIC database. This last point may support the importance of custom disease-specific scores. A disease specific benchmark should be realized to confirm this statement, but the number of recurrent COSMIC mutations is currently insufficient to provide consistent results for CLL, lung and melanoma, preventing a comparison of these four scores. While the community accumulates new data which may be used for this future benchmark, updating this score using larger training sets and higher genome resolution segmentation is needed to validate this approach.
In contrast to the ClinVar database, no selection was applied to the COSMIC database, which included all tumor variants observed in several cancer studies. This limited selection bias is highlighted by the lower prevalence of the protein coding gene regions in the COSMIC dataset (< 50%). A limitation of this benchmark is related to the uncertainty of the true pathogenicity status of COSMIC variants. Passenger mutations which were not removed by recurrence criteria were considered to be pathogenic in this benchmark, and this may have inflated the false negative rates. We used the recurrence as a way to limit the number of included passengers, a common method for selecting pathogenic mutations in coding sequences (Dees et al., 2012; Fu et al., 2014) . The increase of sensitivity and specificity of the different tools with higher number of occurrences suggests that some passengers were removed by this procedure. However, this approach may also remove rare pathogenic mutations and may retain some high frequency passenger mutations from unstable fragile genome regions. Nevertheless, it is accepted that the majority of the COSMIC somatic mutations are passengers. Some of them are located in genome regions in which there is increased interest, such as pseudogenes (Poliseno et al., 2015) or long non-coding RNA (Yarmishyn and Kurochkin, 2015) . Moreover, the variants that occur with greater frequency ( 20 occurrences), annotated as lincRNA and pseudogenes, were located in highly conserved regions [Phastcons (Siepel et al., 2005) conservation score 1], suggesting that these mutations occurred in regions under purifying selection. This includes the most frequently occurring variant of the database (71 occurrences, Supplementary Table S11) which is one of the well known non-coding driver mutations of the TERT promoter (Egberts et al., 2014; Liu and Xing, 2016) . Other frequently occurring COSMIC variants were identified by a low SOM score, characteristic of hypomutated regions in cancer (Li et al., 2015a) .
The frequently occurring variants located in hypomutated regions are favored candidates for important functional roles in tumor cells.
Misclassified passengers in the COSMIC pathogenic database are expected to affect the true and false negative rates, but not the true and false positive rates. Thus, this may not explain the low precision of the tools on the unmatched benchmark. All the tools predicted high proportions of pathogenic variants in our control database. Although the 1KG database may include some pathogenic mutations, even after removing HGMD and ClinVar variants and variants with AF > 1%, the likelihood that the majority of our 100 000 control variants are pathogenic is quite low. The most reasonable assumption is the lack of precision of the tools due to their low resolution genome segmentation in this part of the genome, due to a lack of functional information. A denser annotation of functional features is clearly needed in this part of the genome.
The contrasting benchmark results using these two different pathogenic datasets (ClinVar and COSMIC), especially in terms of genome coverage, suggests that we maybe reached a limit of the current approaches that rely from evidence for germline selection (through modeling assumption and/or using training set which were originally constituted from conservation-based results such as ClinVar or HGMD). All current tools performed very well on genome variants close to the protein coding regions, but their performance on the other regions remains to be demonstrated. Mutations on regulatory element may be less conserved because of their smaller impact on the organism, inducing a lack of performance of the current tools in these regions. A new way to explore the non-coding genome could be to investigate the cumulative effect of different variants that co-occur in tumor. However, this task remains computationally difficult, all the more so that all SNPs should be analyzed (not only somatic mutations) to take into account potential predisposition.
Conclusion
Current variant prioritization tools are rather successful in genomic regions covered by the ClinVar database. CADD had a higher precision than competitors in this exercise. In addition to its solid results, this tool is based on the germline conservation concept, which allows circumventing classical overfitting issues due to the sampling bias of pathogenic variant training sets, such as those used by FATHMM-MKL or GWAVA. In our benchmark based on the COSMIC database, the GWAVA, FATHMM-MKL and SOM liver scores performed the best, but the performance of all scores was moderate on the ClinVar benchmark. The somatic conservation concept is promising in this context, but the related model should be improved. As a large fraction of COSMIC mutations are intergenic, these moderate results may be due to the low resolution of the algorithms in this part of the genome, due in part to the sparsity of features. Moreover, the algorithms compared in this benchmark were developed to detect variants with strong independent deleterious effects, and may fail to detect variants with low effect, e.g. regulatory elements, and potential synergy with other variants. On the other hand, the potential presence of passenger mutations in the COSMIC database may artificially decrease the prediction sensitivity. ClinVar's selection bias and uncertainty about the pathogenicity of COSMIC variants do not allow us to reach a definite conclusion about this software ranking.The development of a gold standard as consistent as ClinVar for non-coding regions (for pathogenic and benign variants) will be necessary to confirm these results and improve the performance of algorithms based on known pathogenic variant training sets. Another important source of prediction improvement will come from biological methods allowing a denser and more accurate annotation of functional features in the non-coding genome.
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